Substance / Medication

Mesna

Overview

Active Ingredient
mesna
RxNorm CUI
44

Indications

Mesna injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia.

Labeler: Eugia US LLCUpdated: 2026-01-27T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Warnings and Precautions (5.1) [see] Mesna injection is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: A cohort study and comprehensive literature review.
Almalag Haya M, Alasmari Sarah S, Alrayes Mounerah H et al. · J Oncol Pharm Pract · 2021
PMID: 32356687Meta-Analysis
In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna.
Cutler M J, Urquhart B L, Velenosi T J et al. · J Clin Pharmacol · 2012
PMID: 21505084RCT
MESNA (sodium 2-mercaptoethanesulfonate) for prevention of contrast medium-induced nephrotoxicity - controlled trial.
Ludwig U, Riedel M K, Backes M et al. · Clin Nephrol · 2011
PMID: 21426884RCT
Mesna for the treatment of hyperhomocysteinemia in hemodialysis patients.
Cutler Murray J, Urquhart Bradley L, Freeman David J et al. · Blood Purif · 2009
PMID: 19270449RCT
Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.
Urquhart Bradley L, Freeman David J, Cutler Murray J et al. · Clin J Am Soc Nephrol · 2008
PMID: 18337551RCTFull text (PMC)
Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis.
Lima Marcos Venício Alves, Ferreira Francisco Valdeci, Macedo Francisco Yuri Bulcão et al. · Cancer Chemother Pharmacol · 2007
PMID: 16947012RCT
Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
Hammer Kathryn J, Copeland Vanessa C, Loggers Elizabeth T et al. · Am J Clin Oncol · 2020
PMID: 32235164Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mesna (substance)
SNOMED CT
386922000
UMLS CUI
C0000294
RxNorm CUI
44
Labeler
Eugia US LLC

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.